Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 17 Apr 2015 Status changed from active, no longer recruiting to discontinued as per M.D. Anderson Cancer Center.
- 15 Apr 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 23 Sep 2014 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History